NCT06955520View on ClinicalTrials.gov

Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM

NARecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

December 10, 2027

Study Completion Date

December 25, 2028

Conditions
GERD
Interventions
DRUG

Vonoprazan

a potassium-competitive acid blocker (P-CAB), offers superior acid suppression and may provide enhanced healing in post-POEM reflux esophagitis.

DRUG

Esomeprazole 40mg

It is a proton pump inhibitor which reduces the excessive acid secretion in the stomach and it heals grade B esophagitis (\>5mm ulcer between two mucosal folds in esophagus)

Trial Locations (1)

500082

RECRUITING

Asian Institute of Gastroenterology /Aig Hospitals, Hyderabad

All Listed Sponsors
lead

Asian Institute of Gastroenterology, India

OTHER